

References

- Alemzadeh, R., Gammeltoft, K., & Matteson, K. (1996). Efficacy of low-dose dextromethorphan in the treatment of nonketotic hyperglycinemia. *Pediatrics*, *97*, 924–926.
- Brusilow, S., Tinker, J., & Batshaw, M. L. (1980). Amino acid acylation: A mechanism of nitrogen excretion in inborn errors of urea synthesis. *Science*, *207*, 659.
- Cedarbaum, S. (2002). Phenylketonuria: An update. *Current Opinion in Pediatrics*, *14*, 702–706.
- Chan, H., & Butterworth, R. F. (2003). Cell-selective effects of ammonia on glutamate transporter and receptor function in the mammalian brain. *Neurochemistry International*, *43*, 525–532.
- Chuang, D. T., Davie, J. R., Wynn, R. M., Chuang, J. L., Koyatam, H., & Cox, R. P. (1995). Molecular basis of maple syrup urine disease and stable correction by retroviral gene transfer. *The Journal of Nutrition*, *125*, 1766S–1772S.
- Deutsch, S. I., Rosse, R. B., & Mastropaolo, J. (1998). Current status of NMDA antagonist interventions in the treatment of nonketotic hyperglycinemia. *Clinical Neuropharmacology*, *21*, 71–79.
- Diamond, A., & Herzberg, C. (1996). Impaired sensitivity to visual contrast in children treated early and continuously for phenylketonuria. *Brain*, *119*, 523–538.
- Dudman, N. P., Guo, X. W., Gordon, R. B., Dawson, P. A., & Wilcken, D. E. (1996). Human homocysteine catabolism: Three major pathways and their relevance to development of arterial occlusive disease. *The Journal of Nutrition*, *126*(Suppl. 4), 295s–300s.
- Eisensmith, R. C., & Woo, S. L. (1991). Phenylketonuria and the phenylalanine hydroxylase gene. *Molecular Biology and Medicine*, *8*, 3–10.
- Felipo, V., & Butterworth, R. (2002). Neurobiology of ammonia. *Progress in Neurobiology*, *67*,

259–279.

- Guldberg, P., Levy, H. L., Hanley, W. B., et al. (1996). Phenylalanine hydroxylase gene mutations in the United States: Report from the Maternal PKU Collaborative Study. *American Journal of Human Genetics*, *59*, 84–94.
- Hommel, F. A. (1994). Loss of neurotransmitter receptors by hyperphenylalaninemia in the HPH-5 mouse brain. *Acta Paediatrica Supplement*, *407*, 120–121.
- Infant, J. P., & Huszagh, V. A. (2001). Impaired arachidonic (20:4n-6) and docosahexaenoic (22:6n-3) acid synthesis by phenylalanine metabolites as etiological factors in the neuropathology of phenylketonuria. *Molecular Genetics and Metabolism*, *72*, 185–198.
- Jan, W., Zimmerman, R. A., Wang, Z. J., Berry, G. T., Kaplan, P. B., & Kaye, E. M. (2003). MR diffusion imaging and MR spectroscopy of maple syrup urine disease during acute metabolic decompensation. *Neuroradiology*, *45*, 393–399.
- Kahler, S. G., & Fahey, M. C. (2003). Metabolic disorders and mental retardation. *American Journal of Medical Genetics*, *117C*, 31–41.
- Kaplan, P., Mazur, A., Field, M., Berlin, J. A., Berry, G. T., Heidenreich, R., et al. (1991). Intellectual outcome in children with maple syrup urine disease. *Journal of Pediatric*, *119*, 46–50.
- Kaufman, S. (1983). Hyperphenylalaninaemia caused by defects in biopterin metabolism. *Journal of Inherited Metabolic Disease*, *8*(Suppl. 1), 20–27.
- Kikuchi, G. (1973). The glycine cleavage system: Composition, reaction mechanism and physiological significance. *Molecular and Cellular Biochemistry*, *1*, 169–175.
- Kluijtmans, L. A., Boers, G. H., Stevens, E. M., et al. (1996). Defective cystathionine beta-synthase regulation by S-adenosyl-methionine in a partially pyridoxine responsive

- homocystinuria patient. *The Journal of Clinical Investigation*, 98, 285–289.
- Koch, R., Moseley, K. D., Yano, S., Nelson, M., Jr., & Moats, R. A. (2003). Large neutral amino acid therapy and phenylketonuria: A promising approach to treatment. *Molecular Genetics and Metabolism*, 79, 110–113.
- Kraus, J. P. (1994). Molecular basis of phenotype expression in homocystinuria. Komrower Lecture. *Journal of Inherited Metabolic Disease*, 17, 383–390.
- Levy, H. L., & Ghavami, M. (1996). Maternal phenylketonuria: A metabolic teratogen. *Teratology*, 53, 176–184.
- Maestri, N. E., Hauser, E. R., Bartholomew, D., & Brusilow, S. W. (1991). Prospective treatment of urea cycle disorders. *The Journal of Pediatrics*, 119, 923.
- Maestri, N. E., Brusilow, S. W., Clissold, D. B., & Bassett, S. S. (1996). Long-term treatment of girls with ornithine transcarbamylase deficiency. *The New England Journal of Medicine*, 335, 855–859.
- Mandel, H., Brenner, B., Berant, M., et al. (1996). Coexistence of hereditary homocystinuria and factor V Leiden—effect on thrombosis. *The New England Journal of Medicine*, 334, 763–768.
- Morton, D. H., Strauss, K. A., Robinson, D. L., Puffenberger, E. G., & Kelley, R. I. (2002). Diagnosis and treatment of maple syrup disease: A study of 36 patients. *Pediatrics*, 109, 999–1008.
- Mueller, G. M., McKenzie, L. R., Homanics, G. E., Watkins, S. C., Robbins, P. D., & Paul, H. S. (1995). Complementation of defective leucine decarboxylation in fibroblasts from a maple syrup urine disease patient by retrovirus-mediated gene transfer. *Gene Therapy*, 2, 461–468.

- Pietz, J., Rupp, A., Ebinger, F., et al. (2003). Cerebral energy metabolism in phenylketonuria: Findings by quantitative *in vivo* ^{31}P MR spectroscopy. *Pediatric Research*, *53*, 654–662.
- Scriver, C. R., Beaudet, A. L., Sly, W. S., & Valle, D. (2001). *The Metabolic and Molecular Basis of Inherited Disease*. New York: McGraw Hill.
- Shefer, S., Tint, G. S., Jean-Guillaume, D., et al. (2000). Is there a relationship between 3-hydroxy-3-methylglutaryl coenzyme a reductase activity and forebrain pathology in the PKU mouse? *Journal of Neuroscience Research*, *61*, 549–563.
- Smith, C. B., & Kang, J. (2000). Cerebral protein synthesis in a genetic model of phenylketonuria. *Proceedings of the National Academy of Sciences of the United States of America*, *97*, 11014–11019.
- Steiner, R. D., Sweetser, D. A., Rohrbaugh, J. R., Dowton, S. B., Toone, J. R., & Applegarth, D. A. (1996). Nonketotic hyperglycinemia: Atypical clinical and biochemical manifestations. *The Journal of Pediatrics*, *128*, 243–246.
- Van Hove, J. L., Kishnani, P., Muenzer, J., et al. (1995). Benzoate therapy and carnitine deficiency in non-ketotic hyperglycinemia. *American Journal of Medical Genetics*, *59*, 444–453.
- Wagner, M., Coelho, D. M., Barschak, A. G., et al. (2000). Reduction of large neutral amino acid concentrations in plasma and CSF of patients with maple syrup urine disease. *Journal of Inherited Metabolic Disease*, *23*, 505–512.
- White, D. A., Nortz, M. J., Mandernach, T., Huntington, K., & Steiner, R. D. (2001). Deficits in memory strategy use related to prefrontal dysfunction during early development: Evidence from children with phenylketonuria. *Neuropsychology*, *15*, 221–229.
- Willard-Mack, C. L., Koehler, R. C., Hirata, T., et al. (1996). Inhibition of glutamine synthetase

reduces ammonia-induced astrocyte swelling in rat. *Neuroscience*, 71, 589–599.

Ye, X., Robinson, M. B., Batshaw, M. L., Furth, E. E., Smith, I., & Wilson, J. M. (1996).

Prolonged metabolic correction in adult ornithine transcarbamylase-deficient mice with adenoviral vectors. *The Journal of Biological Chemistry*, 271, 3639–3646.

Yudkoff, M., Daikhin, Y., Nissim, I., Jawad, A., Wilson, J., & Batshaw, M. B. (1996). *In vivo*

nitrogen metabolism in ornithine transcarbamylase deficiency. *The Journal of Clinical Investigation*, 98, 2167–2173.